A novel nonsense mutation in exon 9 in the extracellular matrix protein 1 gene associated with lipoid proteinosis: A case report

Feras M Ghazawi1, Etienne Saint-Cyr Proulx2,3 and Fatemeh Jafarian4

Abstract
Lipoid proteinosis is a rare autosomal recessive genodermatosis that is caused by loss-of-function mutations in the extracellular matrix protein 1 gene. This study identifies a novel nonsense mutation in exon 9 of the extracellular matrix protein 1 gene associated with lipoid proteinosis, contributing to recent advances in our understanding of the molecular genetics underlying this disease. It is important to identify the mutations in the extracellular matrix protein 1 gene that are associated with lipoid proteinosis and how these affect protein function. Understanding the molecular basis for such genetic disorders may lead to novel therapeutic approaches for treating hereditary genodermatoses.

Keywords
Lipoid proteinosis, extracellular matrix protein 1, ECM1, exon 9, nonsense mutation

Introduction
Lipoid proteinosis, also known as Urbach–Wiethe disease or hyalinosis cutis et mucosae, is a very rare autosomal recessive disorder with approximately 400 cases described. It is caused by a genetic defect, resulting in the deposition of amorphous hyaline material in the skin, mucosa, internal organs, and central nervous system. Clinically, lipoid proteinosis is typically characterized by hoarse voice due to mucosal thickening, laryngeal infiltration, and deposit accumulation in the vocal cords that collectively result in increased vocal fold mass and stiffness as well as irregularity and/or reduction in vocal fold mucosal wave. Lipoid proteinosis is also associated with skin thickening, fragility, poor wound healing capacity, development of hyper-, hypo-, or depigmented scarring and characteristic “moniliform blepharosis” beaded papules on eyelids and thickened mucosa of the tongue as well as neurological complications including seizures.

Lipoid proteinosis is caused by loss-of-function mutations in the extracellular matrix protein 1 gene (ECM1). The ECM1 gene is located on chromosome 1q21, next to the epidermal differentiation complex. It comprises 11 exons and encodes four splice variants. ECM1 gene products have been reported to be involved in extracellular matrix formation, cell adhesion, cell signaling, regulation of tissue differentiation and maturation, angiogenesis, and bone formation. However, a clear understanding of their functions remains to be established. More than 50 ECM1 mutations have been reported in the literature, with the majority of mutations (~50%) reported in exons 6 and 7. No effective therapy is available for this condition yet.

Case report
Here we present two brothers aged 16 and 5 years at the time of presentation, who were referred to our clinic for diffuse cutaneous scarring. They presented with a long-standing history of blistering on the face, arms, trunk, and lower limbs during early childhood that had resolved with scarring. Both boys had developed profound hoarse voices within their first...
few months of life. Obstetrical and developmental histories were unremarkable. There was no history of loss of consciousness, headache, or epilepsy. The elder brother was attending high school in good standing. Our patients were the only affected individuals in a sibship of six. The parents were first cousins, and both originated from the Hazara region of Pakistan. Two paternal uncles and a paternal aunt reportedly shared similar cutaneous and vocal symptoms. No neuropsychiatric abnormalities were reported in the patients or their family.

Physical examination of both siblings was notable for confluent pock-like scars on the face, trunk, upper extremities, and small beaded papules lining the eyelids (Figure 1). The patients’ voices were remarkably hoarse. Examination of the oral mucosa revealed normal appearing teeth and a short tongue with infiltrated frenulum in the younger brother. Diffuse waxy skin thickening and verrucous papules were noted over the extensor surfaces of the upper limbs of the elder brother. Neurological exams were within normal limits.

Investigations including complete blood count, serum biochemistry, electroencephalography, and laryngoscopic examination were all within normal limits. Ophthalmologic evaluation revealed mild myopia in the younger brother. No intracranial anomalies were detected on magnetic resonance imaging and computed tomography scans of the brain. Skin biopsies were performed and revealed Periodic acid–Schiff positive diastase-resistant hyaline deposition in the basement membrane, surrounding blood vessels, adnexal epithelia, and the dermo-epidermal junction. Electron microscopy showed thickened vessel walls with embedded pericyte extension within concentric arrays of basement membrane-like material and irregular concentric reduplication at the epidermal basement membrane.

After receiving informed consent, genetic analysis was performed on saliva specimens obtained from both patients and revealed a homozygous G>T transversion (c.1387G>T) predicted to result in a premature stop codon (p.Glu463X) in exon 9 of the ECM1 gene. Our patients were started on acitretin at 0.5 mg/kg/day. The treatment was well tolerated but no objective or subjective improvement of the skin lesions or hoarseness was noted after 6 months and the treatment was discontinued.

**Discussion**

Erich Urbach, an Austrian dermatologist, and Camillo Wiethe, an Austrian otorhinolaryngologist, first described “lipoidosis cutis et mucosae” in 1929.9 Nearly a century later, about 400 cases of lipid proteinosis have been described in the literature. Epidemiologic data for this rare disease is understandably scarce. The Namaqaland region of South Africa is the area of the world that has the highest prevalence of lipid proteinosis cases. Genetic studies performed on all the cases from South African yield the unique c.826C>T mutation, suggesting a founder effect in this population.10,11 Notably, at least 25 patients, including the one identified in the present report, have been described with ECM1 mutations in cases from the Hazara and Rawalpindi districts in Pakistan.12–14 Javeria and colleagues12 reported five separate cases from different families from the Hazara region, but with no genetic analysis. Furthermore, Nasir et al.13 reported 17 living members of a six-generation family from the adjacent Rawalpindi district in Pakistan, affected by lipid proteinosis, and genetic testing revealed insertion in exon 8 of the ECM1 gene. In addition, two siblings from the Rawalpindi district were diagnosed with lipid proteinosis with mutations in exon 6.14 Other patients from other regions from Pakistan were also reported.15 The elevated number of cases from this region with regard to its relatively limited population raises the question whether a founder effect might be present in this population.

It has been reported that the majority (~50%) of mutations reported in the ECM1 gene were on exons 6 and 7.8 Mutation in exon 6 was associated with severe phenotype while mutations in exon 7 were associated with a mild form.9 Only three mutations in the initial first two exons or in the first intron were described.16 The present study highlights a novel mutation in exon 9. To our knowledge, only one additional study described a loss-of-function mutation in exon 9 of the ECM1 gene in a patient with lipid proteinosis.17

Many systemic therapies have been reported for lipid proteinosis including chloroquine phosphate,18 corticosteroids,19 dimethyl sulfoxide,20 D-penicillamine,21 and etretinate.22 However, none of these treatments have shown clear and lasting benefits. More recently, acitretin has been suggested to improve skin and hoarseness.23–25

In summary, we report a novel nonsense mutation (c.1387G>T) in exon 9 of the ECM1 gene associated with lipid proteinosis. Although previous studies have reported improvement of the skin lesions or hoarseness with acitretin, no improvement was observed in our case. As it is the case for all rare diseases, large randomized studies are not feasible and the search for an effective therapeutic option relies on trial and error. Emerging treatments including Er:YAG (erbium-doped yttrium aluminum garnet) laser to ablate disfiguring lesions,26 and a combination regimen of fractional carbon dioxide and non-ablative radio frequency were recently reported efficacious in the cosmetic treatment of the scars by this disease.27 Further research into the pathophysiology of lipid proteinosis will hopefully provide further insight to guide future therapeutic trials.

**Declaration of conflicting interests**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Informed consent

It was obtained from the parents of the children who are presented in the study.

References

1. Sercu S, Zhang M, Oyama N, et al. Interaction of extracellular matrix protein 1 with extracellular matrix components: ECM1 is a basement membrane protein of the skin. J Invest Dermatol 2008; 128: 1397–1408.
2. Chen Z, Calawerts W, Zhang Y, et al. A case report: hybrid treatment approach to lipoid proteinosis of the larynx. J Voice 2017; 31: 128.e15–128.e19.
3. Hamada T, McLean WH, Ramsay M, et al. Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum Mol Genet 2002; 11: 833–840.
4. Smits P, Pounay Y, Karperien M, et al. Differentiation-dependent alternative splicing and expression of the extracellular matrix protein 1 gene in human keratinocytes. J Invest Dermatol 2000; 114: 718–724.
5. Lee KM, Num K, Oh S, et al. Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. Breast Cancer Res 2014; 16: 479.
6. Han Z, Ni J, Smits P, et al. Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J 2001; 15: 988–994.
7. Deckers MM, Smits P, Karperien M, et al. Recombinant human extracellular matrix protein 1 inhibits alkaline phosphatase activity and mineralization of mouse embryonic metatarsals in vitro. Bone 2001; 28: 14–20.
8. Lupo I, Cefalu AB, Bongiorno MR, et al. A novel mutation of the extracellular matrix protein 1 gene (ECM1) in a patient with lipoid proteinosis (Urbach–Wiethe disease) from Sicily. Br J Dermatol 2005; 153: 1019–1022.
9. Urbach E and Wiethe C. Lipoidosis cutis et mucosae. Virchows Arch Patholog Anat Physiol Klinische Medizin 1929; 273: 285–319.
10. Van Hougenhouck-Tulleken W, Chan I, Hamada T, et al. Clinical and molecular characterization of lipoid proteinosis in Namaqualand, South Africa. Br J Dermatol 2004; 151: 413–423.
11. Gordon H, Gordon W and Botha V. Lipoid proteinosis in an inbred Namaqualand community. Lancet 1969; 1: 1032–1035.
12. Javeria J, Marium M, Samad F, et al. Urbach–Wiethe disease: experience at a tertiary care hospital in Abbottabad, Pakistan. J Ayub Med Coll Abbottabad 2008; 20(4): 86–89.
13. Nasir M, Latif A, Ajmal M, et al. A novel homozygous 62-bp insertion in ECM1 causes lipoid proteinosis in a multigeneration Pakistani family. Br J Dermatol 2009; 161: 688–690.
14. Nasir M, Latif A, Ajmal M, et al. Molecular analysis of lipoid proteinosis: identification of a novel nonsense mutation in the ECM1 gene in a Pakistani family. Diagn Pathol 2011; 6: 69.
15. Shahid SM, Azhar A, Nawab SN, et al. Single nucleotide substitution mutations and polymorphisms in ECM1 gene in lipoid proteinosis in siblings of a Pakistani family. Afr J Biotech 2011; 10: 10825–10830.
16. Chanl, Liu L, Hamada T, et al. The molecular basis of lipoid proteinosis: mutations in extracellular matrix protein 1. Exp Dermatol 2007; 16: 881–890.
17. Liu W, Xu W, Yang X, et al. A novel missense mutation of the ECM1 gene in a Chinese patient with lipoid proteinosis. Clin Exp Dermatol 2012; 37: 28–30.
18. Scott F and Findlay G. Hyalinosis cutis et mucosae (lipoid proteinosis). South Afr Med J 1960; 34: 189–195.
19. Zhang R, Liu Y, Xue Y, et al. Treatment of lipoid proteinosis due to the p.C220G mutation in ECM1, a major allele in Chinese patients. J Transl Med 2014; 12: 85.
20. Wong CK and Lin CS. Remarkable response of lipoid proteinosis to oral dimethyl sulphoxide. Br J Dermatol 1988; 119: 541–544.
21. Kayaa TI, Kokturk A, Tursen U, et al. D-penicillamine treatment for lipoid proteinosis. Pediatr Dermatol 2002; 19: 359–362.
22. Gruber F, Manestar D, Stasic A, et al. Treatment of lipoid proteinosis with etretinate. *Acta Derm Venereol* 1996; 76: 154–155.

23. Luo XY, Li Q, Tan Q, et al. Treatment of lipoid proteinosis with acitretin in two patients from two unrelated Chinese families with novel nonsense mutations of the ECM1 gene. *J Dermatol* 2016; 43: 804–807.

24. Gunduz O, Sahiner N, Atasoy P, et al. Acitretin treatment for lipoid proteinosis. *Case Rep Dermatol Med* 2012; 2012: 324506.

25. Toosi S and Ehsani AH. Treatment of lipoid proteinosis with acitretin: a case report. *J Eur Acad Dermatol Venereol* 2009; 23: 482–483.

26. Caliskan E, Acikgoz G, Tunca M, et al. Treatment of lipoid proteinosis with ablative Er:YAG laser resurfacing. *Dermatol Ther* 2015; 28: 291–295.

27. Madura C, Priya A and Chandrashekar BS. Lipoid proteinosis: skin resurfacing with combination of fractional CO2 and non-ablative radio frequency: a rare case report. *J Cutan Aesthet Surg* 2018; 11: 91–94.